Tryptamine Therapeutics (ASX:TYP) has reached another critical milestone in its program to treat Binge Eating Disorder (BED), confirming the enrolment of a second participant in its clinical trial of TRP-8803, an intravenous formulation of psilocin. …
Tryp advances psilocin trial for binge eating disorder as second patient enrolled
November 18, 2025 Australian Biotech
Latest Video
Georgia Forrest
New Stories
-
CSL expands US manufacturing with $1.5bn investment to boost plasma therapy production
March 10, 2026 - - Latest News -
Labor’s FoI backdown is a welcome victory for transparency and accountability
March 10, 2026 - - Latest News -
Mark Butler steps in to block eye injection funding change after patient warnings
March 10, 2026 - - Latest News -
Pharmac says new agreement has improved access to treatment for New Zealanders
March 10, 2026 - - Latest News -
Island Pharmaceuticals expands antiviral program through Burnet Institute collaboration
March 9, 2026 - -
New cancer research highlights potential of narmafotinib to koost KRAS Inhibitor therapies
March 9, 2026 - - Australian Biotech -
Lateral Pharma secures key U.S. patent for novel neuropathic pain therapy
March 9, 2026 - - Australian Biotech